The positive news provided a brief lift for Novo Nordisk shares, though the stock remains down for the year. The company faces a complex path ahead, struggling to balance surging consumer demand against the practical limitations of its supply chain. Beyond production hurdles, the firm must navigate an increasingly crowded anti-obesity market, where both generic alternatives and aggressive branded competition continue to challenge its dominance and weigh on Wall Street sentiment.